Transient thyrotoxicosis during nivolumab treatment

M. J. van Kooten; G. van den Berg; A. W. J. M. Glaudemans; T. J. N. Hiltermann; H. J. M. Groen; A. Rutgers; T. P. Links

Transient thyrotoxicosis during nivolumab treatment

M. J. van Kooten
, G. van den Berg^*
, A. W. J. M. Glaudemans
, T. J. N. Hiltermann
, H. J. M. Groen
, A. Rutgers
, T. P. Links

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Scopus)

Abstract

Two patients presented with transient thyrotoxicosis within 2-4 weeks after starting treatment with nivolumab. This thyrotoxicosis turned into hypothyroidism within 6-8 weeks. Temporary treatment with a beta blocker may be sufficient.

Original language	English
Pages (from-to)	204-207
Number of pages	4
Journal	The Netherlands Journal of Medicine
Volume	75
Issue number	5
Publication status	Published - Jun-2017

Keywords

Checkpoint inhibition
thyrotoxicosis
thyroiditis
lung cancer
immune related adverse reactions
IMMUNE CHECKPOINT INHIBITORS
CELL LUNG-CANCER
ADVANCED MELANOMA
PEMBROLIZUMAB
TOXICITIES
DOCETAXEL

Access to Document

http://www.njmonline.nl/article_ft.php?a=1856&d=1230&i=206

Handle.net

Persistent link

Embargoed Document

Transient thyrotoxicosis during nivolumab treatment
Final publisher's version, 404 KB
Request copy

Cite this

@article{4f7cdfdedafc4345bae1f110e7106f34,

title = "Transient thyrotoxicosis during nivolumab treatment",

abstract = "Two patients presented with transient thyrotoxicosis within 2-4 weeks after starting treatment with nivolumab. This thyrotoxicosis turned into hypothyroidism within 6-8 weeks. Temporary treatment with a beta blocker may be sufficient.",

keywords = "Checkpoint inhibition, thyrotoxicosis, thyroiditis, lung cancer, immune related adverse reactions, IMMUNE CHECKPOINT INHIBITORS, CELL LUNG-CANCER, ADVANCED MELANOMA, PEMBROLIZUMAB, TOXICITIES, DOCETAXEL",

author = "\{van Kooten\}, \{M. J.\} and \{van den Berg\}, G. and Glaudemans, \{A. W. J. M.\} and Hiltermann, \{T. J. N.\} and Groen, \{H. J. M.\} and A. Rutgers and Links, \{T. P.\}",

year = "2017",

month = jun,

language = "English",

volume = "75",

pages = "204--207",

journal = "The Netherlands Journal of Medicine",

issn = "0300-2977",

publisher = "van Zuiden Communications BV.",

number = "5",

}

TY - JOUR

T1 - Transient thyrotoxicosis during nivolumab treatment

AU - van Kooten, M. J.

AU - van den Berg, G.

AU - Glaudemans, A. W. J. M.

AU - Hiltermann, T. J. N.

AU - Groen, H. J. M.

AU - Rutgers, A.

AU - Links, T. P.

PY - 2017/6

Y1 - 2017/6

N2 - Two patients presented with transient thyrotoxicosis within 2-4 weeks after starting treatment with nivolumab. This thyrotoxicosis turned into hypothyroidism within 6-8 weeks. Temporary treatment with a beta blocker may be sufficient.

AB - Two patients presented with transient thyrotoxicosis within 2-4 weeks after starting treatment with nivolumab. This thyrotoxicosis turned into hypothyroidism within 6-8 weeks. Temporary treatment with a beta blocker may be sufficient.

KW - Checkpoint inhibition

KW - thyrotoxicosis

KW - thyroiditis

KW - lung cancer

KW - immune related adverse reactions

KW - IMMUNE CHECKPOINT INHIBITORS

KW - CELL LUNG-CANCER

KW - ADVANCED MELANOMA

KW - PEMBROLIZUMAB

KW - TOXICITIES

KW - DOCETAXEL

M3 - Article

C2 - 28653941

SN - 0300-2977

VL - 75

SP - 204

EP - 207

JO - The Netherlands Journal of Medicine

JF - The Netherlands Journal of Medicine

IS - 5

ER -

Transient thyrotoxicosis during nivolumab treatment

Abstract

Keywords

Access to Document

Handle.net

Embargoed Document

Fingerprint

Cite this